Condition: Advanced Esophageal Cancer
Interventions: Biological: Anti-MUC1 CAR-T cells; Biological: PD-1 knockout Engineered T cells; Combination Product: CAR-T combined with PD-1 Knockout T cells
Sponsors: The First Affiliated Hospital of Guangdong Pharmaceutical University; Guangzhou Anjie Biomedical Technology Co;LTD
Recruiting
https://ift.tt/2RUNxxD
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
-
Publication date: September 2017 Source: European Journal of Surgical Oncology (EJSO), Volume 43, Issue 9 http://ift.tt/2gezJ2D
-
Publication date: January–February 2018 Source: Materials Today, Volume 21, Issue 1 Author(s): David Bradley http://ift.tt/2BP...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου